David Hoang
Stock Analyst at Citigroup
(0.52)
# 3,022
Out of 4,412 analysts
17
Total ratings
15.38%
Success rate
-12.23%
Average return
Main Sectors:
Top Industries:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $125 → $127 | $71.71 | +77.10% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Initiates: Buy | $16 | $8.98 | +78.17% | 1 | Mar 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $38 → $30 | $16.71 | +80.67% | 2 | Mar 12, 2024 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $16 | $7.62 | +109.97% | 1 | Mar 7, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $160 → $172 | $128.77 | +33.57% | 3 | Feb 29, 2024 | |
| LBPH Longboard Pharmaceuticals | Initiates: Buy | $40 | $19.72 | +102.84% | 1 | Feb 16, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $141 → $140 | $135.99 | +2.95% | 2 | Feb 8, 2024 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $62 | $40.50 | +53.09% | 1 | Jan 4, 2024 | |
| DNLI Denali Therapeutics | Initiates: Buy | $32 | $15.43 | +107.39% | 1 | Dec 13, 2023 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Neutral | $220 | $143.31 | +53.51% | 1 | Apr 26, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | $80 | $22.12 | +261.66% | 1 | Apr 26, 2023 | |
| GOSS Gossamer Bio | Downgrades: Neutral | $3 | $0.67 | +349.10% | 1 | Dec 7, 2022 |
Axsome Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $125 → $127
Current: $71.71
Upside: +77.10%
Solid Biosciences
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $8.98
Upside: +78.17%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Buy
Price Target: $38 → $30
Current: $16.71
Upside: +80.67%
Voyager Therapeutics
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $7.62
Upside: +109.97%
Sarepta Therapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $160 → $172
Current: $128.77
Upside: +33.57%
Longboard Pharmaceuticals
Feb 16, 2024
Initiates: Buy
Price Target: $40
Current: $19.72
Upside: +102.84%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $141 → $140
Current: $135.99
Upside: +2.95%
Xenon Pharmaceuticals
Jan 4, 2024
Initiates: Buy
Price Target: $62
Current: $40.50
Upside: +53.09%
Denali Therapeutics
Dec 13, 2023
Initiates: Buy
Price Target: $32
Current: $15.43
Upside: +107.39%
Alnylam Pharmaceuticals
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $143.31
Upside: +53.51%
Arrowhead Pharmaceuticals
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $22.12
Upside: +261.66%
Gossamer Bio
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.67
Upside: +349.10%